The results showed that the h‐mIL‐6R mAb and Tocilizumab treatment significantly decreased serum concentrations of these four cytokines in the LPS‐induced SIRS mice, implying that the IL‐6R mAb treatment could contribute to alleviating systemic inflammation in SIRS (Figure 3B). This evidence concerns the gene IL6R and systemic inflammatory response syndrome.